Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare the safety and tolerability of temsirolimus and sorafenib when used as single agents in the second-line setting in subjects with advanced RCC who have failed prior first-line treatment with sunitinib due to progressive disease (PD). To compare the efficacy, as measured by PFS (determined by a centralized independent assessment), of temsirolimus and sorafenib when used as single agents in the second-line setting in subjects with advanced RCC who have failed prior first-line treatment with sunitinib.
Critère d'inclusion
- Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy